Top Midday Decliners

02:27 PM EST, 11/04/2026 (MT Newswires) -- Nurix Therapeutics (NRIX) said late Tuesday that Sanofi (SNY) has decided to discontinue the phase 1 clinical trial and terminate development of SAR448272, an oral STAT6 degrader co-developed under the companies' 2019 partnership. Nurix shares plunged 38% as intraday trading volume jumped to over 13.5 million from a daily average of about 1.78 million. Fidelity National Information Services (FIS) stock plunged 25% after the company trimmed its 2026 outlook. JPMorgan downgraded the company's shares to neutral from overweight. Intraday trading volume surged to over 23.8 million shares from a daily average of about 6.0 million. Price: 16.42, Change: -9.40, Percent Change: -36.41